Aro Biotherapeutics

📍 Philadelphia, United States🗓 Founded 2018👥 49 employees💰 Last funded Jun 2024
Biotechnology🌐 arobiotx.com
Website LinkedIn
Unlocking the Potential of Genetic Medicines Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
3
Total investors
1
Early stage
1
Mid stage
1
Late stage
2018
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
Sweden
1
Investor activity2020–2024 · investors recorded per year
202012021120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Aro Biotherapeutics?
Aro Biotherapeutics has 3 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did Aro Biotherapeutics last raise funding?
The most recent investment in Aro Biotherapeutics recorded on gritt.io was in June 2024.
When was Aro Biotherapeutics founded?
Aro Biotherapeutics was founded in 2018.
What industry is Aro Biotherapeutics in?
Aro Biotherapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Aro Biotherapeutics based?
Aro Biotherapeutics is headquartered in Philadelphia, United States.